AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of -$0.25 per share, beating estimates of -$0.60 by $0.35. The company also reported revenue of $259,690,000, beating estimates of $254,927,967 by $4,762,033.
You can see Quiver Quantitative's $AXSM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AXSOME THERAPEUTICS Insider Trading Activity
AXSOME THERAPEUTICS insiders have traded $AXSM stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:
- HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 4 sales selling 149,000 shares for an estimated $34,441,528.
- NICK PIZZIE (Chief Financial Officer) sold 33,000 shares for an estimated $7,922,970
- MARK COLEMAN has made 0 purchases and 4 sales selling 18,180 shares for an estimated $4,179,577.
- MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 14,750 shares for an estimated $3,169,270.
- SUSAN MAHONY has made 0 purchases and 2 sales selling 600 shares for an estimated $145,017.
- ROGER JEFFS has made 0 purchases and 2 sales selling 572 shares for an estimated $141,655.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AXSOME THERAPEUTICS Hedge Fund Activity
We have seen 278 institutional investors add shares of AXSOME THERAPEUTICS stock to their portfolio, and 202 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 809,136 shares (-20.7%) from their portfolio in Q2 2026, for an estimated $198,052,218
- PRICE T ROWE ASSOCIATES INC /MD/ removed 674,166 shares (-51.2%) from their portfolio in Q2 2026, for an estimated $165,015,611
- MILLENNIUM MANAGEMENT LLC added 535,330 shares (+2578.9%) to their portfolio in Q2 2026, for an estimated $131,032,724
- WELLINGTON MANAGEMENT GROUP LLP removed 491,386 shares (-42.9%) from their portfolio in Q2 2026, for an estimated $120,276,551
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 478,544 shares (-64.9%) from their portfolio in Q2 2026, for an estimated $117,133,214
- DEEP TRACK CAPITAL, LP removed 400,000 shares (-36.4%) from their portfolio in Q2 2026, for an estimated $97,908,000
- JANE STREET GROUP, LLC added 399,917 shares (+9806.7%) to their portfolio in Q2 2026, for an estimated $97,887,684
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AXSOME THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $AXSM recently. We have seen 3 analysts offer price targets for $AXSM in the last 6 months, with a median target of $300.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $290.0 on 07/08/2026
- Leonid Timashev from RBC Capital set a target price of $304.0 on 07/07/2026
- Joseph Thome from TD Cowen set a target price of $300.0 on 06/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
